Table 2 Univariable and multivariable cox analysis of OS before propensity matched analysis
Variable | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Age (≥60/< 60, year) | 1.279 | 0.857–1.908 | 0.229 | – | – | – |
Sex (Men/Women) | 1.443 | 0.95–2.193 | 0.085 | – | – | – |
HBsAg (yes/no) | 1.044 | 0.719–1.517 | 0.821 | – | – | – |
HCV antibody (yes/no) | 2.293 | 0.722–7.283 | 0.159 | – | – | – |
AFP (≥20/< 20, ng/mL) | 2.819 | 0.68–11.682 | 0.153 | – | – | – |
CEA (≥5/<5, ng/mL) | 1.844 | 0.643–5.29 | 0.255 | – | – | – |
CA19–9 (≥37/<37, U/mL) | 2.069 | 0.639–6.702 | 0.225 | – | – | – |
Liver cirrhosis, yes (%) | 1.252 | 0.857–1.83 | 0.245 | – | – | – |
TB (≥17/< 17, μmol/L) | 0.950 | 0.626–1.443 | 0.810 | – | – | – |
ALB (≥40/<40, g/mL) | 0.759 | 0.530–1.086 | 0.132 | – | – | – |
ALT (≥35/<35, U/L) | 1.327 | 0.941–1.870 | 0.106 | – | – | – |
γ-GT (≥40/<40, U/L) | 2.662 | 1.703–4.163 | < 0.001 | 2.152 | 1.354–3.421 | 0.001 |
PLT (≥10/< 10 103/μL) | 1.005 | 0.665–1.518 | 0.982 | – | – | – |
Prothrombin time, median (range), s | 1.199 | 0.781–1.841 | 0.406 | – | – | – |
Tumour size, cm | 1.769 | 1.235–2.534 | 0.002 | 1.274 | 0.867–1.872 | 0.218 |
Tumour nodularities | 1.167 | 1.055–1.292 | 0.003 | 1.130 | 1.011–1.262 | 0.031 |
Occlusion, min (< 20/≥20) | 0.290 | 0.740–2.250 | 0.369 | – | – | – |
Macrovascular invasion (yes/no) | 1.927 | 1.442–2.576 | < 0.001 | 1.869 | 1.375–2.540 | < 0.001 |
Microvascular invasion (yes/no) | 1.365 | 0.921–2.204 | 0.122 | – | – | – |
Lymphoid metastasis (yes/no) | 2.801 | 1.745–4.495 | < 0.001 | 2.031 | 1.201–3.435 | 0.008 |
Extrahepatic metastasis (yes/no) | 11.435 | 5.262–24.849 | < 0.001 | 6.392 | 2.731–14.961 | < 0.001 |
Preventive TACE (yes/no) | 1.212 | 0.807–1.821 | 0.354 | – | – | – |